2009 gout pharmacology

82
Reginald D Sanders, MD Reginald D Sanders, MD LSU Clinical Pharmacology Drug Therapy of Gout

Upload: amilia-nurrahmah

Post on 27-May-2015

1.329 views

Category:

Health & Medicine


0 download

TRANSCRIPT

Page 1: 2009 gout pharmacology

Reginald D Sanders, MDReginald D Sanders, MD

LSU Clinical Pharmacology

Drug Therapy of Gout

Page 2: 2009 gout pharmacology

Drug therapy of gout - overview

• what is gout?• what happens to patients with gout & why?• what drugs are available for managing gout?• how are those drugs used?

Page 3: 2009 gout pharmacology

Drug therapy of gout

The drugs used in treating gout make sense!

We have excellent drugs for managing gout

Page 4: 2009 gout pharmacology

Drug therapy of gout

What Is Gout?

Page 5: 2009 gout pharmacology

Drug therapy of gout

Case Presentation

Page 6: 2009 gout pharmacology

Case presentation

• 55 y/o male• 12 hours “pain in my big toe & ankle”• went to bed last night feeling fine• felt as if had broken toe this morning• PMH of similar problems in right

ankle & left wrist

Page 7: 2009 gout pharmacology

Case presentation

• can barely walk (due to pain)• right elbow swollen• exam shows left first MTP joint & left

ankle to be red, swollen & tender to touch

• right elbow also swollen

Page 8: 2009 gout pharmacology

Case presentation

• lab studiesserum uric acid = 11.5 mg/dl24-hour uric acid excretion = 300 mg

• left foot X-rays show bony erosion with overhanging edge, medial side of first metatarsal head

Page 9: 2009 gout pharmacology

Case presentation

What does he have?

What can do we do about it?

Page 10: 2009 gout pharmacology

Gout - acute arthritis

acute synovitis, ankle & first MTP

joints

Page 11: 2009 gout pharmacology

Gout - acute bursitis

acute olecranon

bursitis

Page 12: 2009 gout pharmacology

Gouty arthritis - characteristics

• sudden onset• middle aged males• severe pain• distal joints• Intense

inflammation

• recurrent episodes• influenced by diet• bony erosions on Xray

Page 13: 2009 gout pharmacology

Drug therapy of gout

What Happens To Gout Patients & Why?

Page 14: 2009 gout pharmacology

Gout - acute arthritis

acute synovitis, ankle & first MTP

joints

arthrocentesis

Page 15: 2009 gout pharmacology

Monosodium urate crystals

polarized light red compensator

needle shape

negative birefringence

Page 16: 2009 gout pharmacology

Crystal-induced inflammation

PMN is critical

component of crystal-induced

inflammation

crystal deposition

hyperuricemia

protein binding

receptor binding

cytokine release

influx of PMN’s

crystals engulfed

inflammation

Page 17: 2009 gout pharmacology

Gouty arthritis - characteristics

• sudden onset• middle aged males• severe pain• distal joints• intense

inflammation

• recurrent episodes• influenced by diet• bony erosions on

Xray• hyperuricemia

Page 18: 2009 gout pharmacology

Hyperuricemia

productionexcretion

hyperuricemia results when production exceeds excretion

Page 19: 2009 gout pharmacology

Hyperuricemia

productionexcretion

net uric acid loss results when excretion exceeds production

Page 20: 2009 gout pharmacology

Chronic tophaceous gout

tophus = localized deposit of monosodium urate

crystals

Page 21: 2009 gout pharmacology

Gout - tophus

classic location of tophi on helix

of ear

Page 22: 2009 gout pharmacology

Gout - X-ray changes

DIP joint destruction

phalangeal bone cysts

Page 23: 2009 gout pharmacology

Gout - X-ray changes

bony erosions

Page 24: 2009 gout pharmacology

Gout - cardinal manifestations

nephrolithiasis

nephropathy

arthritis tophi

HYPERURICEMIA

acute &

chronic

Page 25: 2009 gout pharmacology

Drug therapy of gout

The Role of Uric Acid in

Gout

Page 26: 2009 gout pharmacology

Hyperuricemia & gout

Serum Uric Acid

Level

> 10 mg/dl

< 7 mg/dl

Annual Incidence

70

0.9

5-Year Prevalenc

e

30%

0.6%

Page 27: 2009 gout pharmacology

Serum uric acid levels & age

3.04.05.06.07.08.09.0

10.011.012.013.0

10 20 30 40 50 60

Age (years)

Gouty Male

Normal Male

Gouty Female

Normal Female

Page 28: 2009 gout pharmacology

Uric acid metabolism

cell breakdown

dietary intake

purine bases

hypoxanthine

xanthine

uric acid

xanthine oxidase

catalyzes hypoxanthine to xanthine & xanthine to

uric acid

Page 29: 2009 gout pharmacology

Renal handling of uric acid

•glomerular filtration

•tubular reabsorption

•tubular excretion

•post-secretory reabsorption

•net excretion

Page 30: 2009 gout pharmacology

Hyperuricemia - mechanisms

hyperuricemia

excessive production

inadequate excretion

Page 31: 2009 gout pharmacology

Hyperuricemia - mechanisms

hyperuricemia

overproducers underexcretors

Page 32: 2009 gout pharmacology

Classifying hyperuricemia

• serum uric acid level• urine uric acid excretion (24-hour)

overproduction underexcretion

serum uric acid high highurine uric acid high normal/ low

Page 33: 2009 gout pharmacology

Gout - problems

• excessive total body levels of uric acid

• deposition of monosodium urate crystals in joints & other tissues

• crystal-induced inflammation

Page 34: 2009 gout pharmacology

Drug therapy of gout

What Drugs Are Available For Treating

Gout?

Page 35: 2009 gout pharmacology

Treating acute gouty arthritis

what strategies might be effective?

Page 36: 2009 gout pharmacology

Treating acute gouty arthritis

• colchicine• NSAID’s• steroids• rest, analgesia, ice, time

Page 37: 2009 gout pharmacology

Drugs used to treat gout

allopurinol

probenecid

febuxostat?

steroids

NSAID’s

colchicine

Acute Arthritis Drugs

Urate Lowering Drugs

rest + analgesia + time

Page 38: 2009 gout pharmacology

Drugs used to treat gout

Acute Arthritis Drugs

allopurinol

probenecid

febuxostat?

steroids

NSAID’s

colchicine

Urate Lowering Drugs

rest + analgesia + time

Page 39: 2009 gout pharmacology

Benjamin Franklin (1706 - 1790)

suggests gout sufferers use

l’Eau Medicinale d'Husson

(secret French medicine containing colchicine)

Page 40: 2009 gout pharmacology

Colchicine - plant alkaloid

colchicum autumnale

(autumn crocus or meadow

saffron)

Page 41: 2009 gout pharmacology

Colchicine

• “only effective in gouty arthritis”• not an analgesic• does not affect renal excretion of uric

acid• does not alter plasma solubility of uric

acid• neither raises nor lowers serum uric acid

Page 42: 2009 gout pharmacology

Colchicine

• mechanism of action poorly understood• reduces inflammatory response to

deposited crystals• diminishes PMN phagocytosis of crystals• blocks cellular response to deposited

crystals

Page 43: 2009 gout pharmacology

Crystal-induced inflammation

PMN is critical

component of crystal-induced

inflammation

crystal deposition

hyperuricemia

protein binding

receptor binding

cytokine release

influx of PMN’s

crystals engulfed

inflammation

Page 44: 2009 gout pharmacology

Colchicine - indications

Dose Indication

hightreatment of acute gouty arthritis

lowprevention of recurrent gouty arthritis

Page 45: 2009 gout pharmacology

Colchicine - toxicity

• gastrointestinal (nausea, vomiting, cramping, diarrhea, abdominal pain)

• hematologic (agranulocytosis, aplastic anemia, thrombocytopenia)

• muscular weakness

adverse effects dose-related & more common when patient has renal or hepatic disease

Page 46: 2009 gout pharmacology

Treating acute gout

What is the role of colchicine in treating acute gouty arthritis?

Page 47: 2009 gout pharmacology

Gout - colchicine therapy

• more useful for daily prophylaxis (low dose)prevents recurrent attackscolchicine 0.6 mg qd - bid

• declining use in acute gout (high dose)

Page 48: 2009 gout pharmacology

Drugs used to treat gout

allopurinol

probenecid

febuxostat?

steroids

NSAID’s

colchicine

Acute Arthritis Drugs

Urate Lowering Drugs

rest + analgesia + time

Page 49: 2009 gout pharmacology

Hyperuricemia - mechanisms

hyperuricemia

excessive production

inadequate excretion

Page 50: 2009 gout pharmacology

Urate-lowering drugs

net reduction in total body pool of uric acid

block production

enhance excretion

Page 51: 2009 gout pharmacology

Gout - urate-lowering therapy

• prevents arthritis, tophi & stones by lowering total body pool of uric acid

• not indicated after first attack• initiation of therapy can worsen or

bring on acute gouty arthritis• no role to play in managing acute gout

Page 52: 2009 gout pharmacology

Drug therapy of gout

Drugs That Block Production of Uric Acid

Page 53: 2009 gout pharmacology

Uric acid metabolism

cell breakdown

dietary intake

purine bases

hypoxanthine

xanthine

uric acid

xanthine oxidase

catalyzes hypoxanthine to xanthine & xanthine to

uric acid

Page 54: 2009 gout pharmacology

Allopurinol (Zyloprim™)

• inhibitor of xanthine oxidase• effectively blocks formation of uric

acid• how supplied - 100 mg & 300 mg

tablets• pregnancy category C

allopurinol

Page 55: 2009 gout pharmacology

Chemical structures

N

N

O

N

N

allopurinol

N

HN

O

N

NH

hypoxanthine

xanthine

N

N

NH

N

HO

OH

Page 56: 2009 gout pharmacology

Uric acid metabolism

cell breakdown

dietary intake

purine bases

hypoxanthine

xanthine

uric acid

allopurinol inhibits

xanthine oxidase

allopurinol

allopurinol

oxypurinol

Page 57: 2009 gout pharmacology

Allopurinol effects

Effect of Allopurinol on Total Serum Levels of Xanthine + Hypoxanthine

Normal 0.15 mg/dl

Allopurinol 0.35 mg/dl

saturation level of xanthine & hypoxanthine > 7 mg/dl

Page 58: 2009 gout pharmacology

Allopurinol effect

Component Serum Level

Hypoxanthine

Xanthine

Uric acid

allopurinol lowers serum uric acid levels

Page 59: 2009 gout pharmacology

Allopurinol

What are the clinical consequences of

blocking production of uric acid?

Page 60: 2009 gout pharmacology

Allopurinol

• 90% absorption from the gut• metabolized to oxypurinol• once daily dosing• lowers serum uric acid levels• lowers urine uric acid levels• side effects rare, but potentially lethal

Page 61: 2009 gout pharmacology

Allopurinol - usage indications

• management of hyperuricemia of gout

• management of hyperuricemia associated with chemotherapy

• prevention of recurrent calcium oxalate kidney stones

Page 62: 2009 gout pharmacology

Allopurinol – black box warning

THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA

ALLOPURINOL SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR OTHER SIGNS OF AN ALLERGIC REACTION

Page 63: 2009 gout pharmacology

Allopurinol - common reactions

• diarrhea, nausea, abnormal liver tests

• acute attacks of gout• rash

Page 64: 2009 gout pharmacology

Allopurinol - serious reactions

• fever, rash, toxic epidermal necrolysis• hepatotoxicity, marrow suppression• vasculitis• drug interactions (ampicillin, thiazides,

mercaptopurine, azathioprine)• death

Page 65: 2009 gout pharmacology

Stevens-Johnson syndrome

target skin lesions

mucous membrane erosions

epidermal necrosis with skin detachment

Page 66: 2009 gout pharmacology

Allopurinol hypersensitivity

• extremely serious problem• prompt recognition required• first sign usually skin rash• more common with impaired renal

function• progression to toxic epidermal

necrolysis & death

Page 67: 2009 gout pharmacology

Febuxostat

• recently approved by FDA (not on market)• oral xanthine oxidase inhibitor• chemically distinct from allopurinol• 94% of patients reached urate < 6.0 mg/dl• minimal adverse events• can be used in patients with renal disease

Page 68: 2009 gout pharmacology

PEG-uricase

• investigational drug• PEG-conjugate of recombinant

porcine uricase• treatment-resistant gout• uricase speeds resolution of tophi• further research needed

Page 69: 2009 gout pharmacology

Drug therapy of gout

Drugs That Enhance Excretion of Uric Acid

Page 70: 2009 gout pharmacology

Renal handling of uric acid

•glomerular filtration

•tubular reabsorption

•tubular excretion

•post-secretory reabsorption

•excretion

Page 71: 2009 gout pharmacology

Uricosuric therapy

• probenecid• blocks tubular reabsorption of uric

acid• enhances urine uric acid excretion• increases urine uric acid level• decreases serum uric acid level

Page 72: 2009 gout pharmacology

Uricosuric therapy

• moderately effective• increases risk of nephrolithiasis• not used in patients with renal disease• frequent, but mild, side effects• some drugs reduce efficacy (e.g.,

aspirin)

Page 73: 2009 gout pharmacology

Uricosuric therapy

• contra-indicationshistory of nephrolithiasiselevated urine uric acid levelexisting renal disease

• less effective in elderly patients

Page 74: 2009 gout pharmacology

Choosing a urate-lowering drug

hyperuricemia

excessive production

inadequate excretion

xanthine

oxidase inhibito

r

uricosuric agent

Page 75: 2009 gout pharmacology

Urate-lowering therapy

• mild gout uricosuric• renal disease allopurinol• nephrolithiasis allopurinol• high 24-hr UUA allopurinol• elderly allopurinol• tophaceous gout allopurinol

Page 76: 2009 gout pharmacology

Treating acute gout

What is the role of urate-lowering drugs like

allopurinol or probenecid in treating acute gouty

arthritis?

Page 77: 2009 gout pharmacology

Urate-lowering therapy

• no anti-inflammatory activity• can precipitate acute gout• can prolong attack of gout• advice?

Page 78: 2009 gout pharmacology

Gout - rule #309

Concept“Don’t mess with the uric acid level”

Don’t change your urate-loweringtherapy during an acute gout attack

Page 79: 2009 gout pharmacology

Gout - therapeutic problems

• renal disease• nephrolithiasis• transplantation• allopurinol allergy

Page 80: 2009 gout pharmacology

Drug therapy of gout

Case Presentation

Page 81: 2009 gout pharmacology

Case presentation - therapy

NSAID

steroid

colchicine (low-dose)

allopurinol

NSAID

days 1-10 days 11-365 days 365+

Page 82: 2009 gout pharmacology

Reginald D Sanders, MDReginald D Sanders, MD

LSU Clinical Pharmacology

Drug Therapy of Gout